Advertisement

Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study

      Abstract

      Purpose

      Single-agent oral chemotherapy is widely used in patients with bone metastases without visceral involvement, especially in hormone receptor–positive metastatic breast cancer (mBC). However, this option has been poorly evaluated in clinical trials.

      Methods

      Eligible patients had mBC with predominantly bone but not visceral metastases, were receiving bisphosphonate therapy, and had previously received endocrine therapy (any setting) but not chemotherapy for mBC. Patients received oral vinorelbine 60 mg/m2 on days 1, 8, 15, and 22 every 4 weeks (escalating to 80 mg/m2 from cycle 2 in the absence of grade 3/4 toxicity) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints included clinical benefit rate (complete/partial response or ≥24 weeks' stable disease), overall survival, and safety.

      Results

      Seventy patients were treated for a median of 6 cycles (range 1-18). Most (73%) continued treatment until disease progression. After 43 months' median follow-up, median PFS was 8.2 months (95% confidence interval [CI], 5.5-9.8). The clinical benefit rate was 56% (95% CI, 43%-68%). Median overall survival was 35.2 months (95% CI, 26.8-47.1). The most common grade 3/4 adverse event was neutropenia (38% of patients); febrile neutropenia was absent. The most common grade 1/2 adverse events were bone pain, fatigue, and gastrointestinal toxicities. Alopecia was infrequent.

      Conclusions

      In patients with hormone receptor–positive mBC, bone disease, and prior endocrine therapy, first-line oral vinorelbine chemotherapy demonstrated long PFS and good tolerability. In this setting, it could be considered as an active oral alternative to intravenous chemotherapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coleman R.E.
        Clinical features of metastatic bone disease and risk of skeletal morbidity.
        Clin Cancer Res. 2006; 12: 6243-6249
        • James J.
        • Evans A.
        • Pinder S.
        • et al.
        Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features.
        Br J Cancer. 2003; 89: 660-665
        • Hess K.R.
        • Pusztai L.
        • Buzdar A.U.
        • Hortobagyi G.N.
        Estrogen receptors and distinct patterns of breast cancer relapse.
        Breast Cancer Res Treat. 2003; 78: 105-118
        • Lee S.J.
        • Park S.
        • Ahn H.K.
        • et al.
        Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer.
        Cancer Res Treat. 2011; 43: 89-95
        • Smid M.
        • Wang Y.
        • Zhang Y.
        • et al.
        Subtypes of breast cancer show preferential site of relapse.
        Cancer Res. 2008; 68: 3108-3114
        • Gerratana L.
        • Fanotto V.
        • Bonotto M.
        • et al.
        Pattern of metastasis and outcome in patients with breast cancer.
        Clin Exp Metastasis. 2015; 32: 125-133
        • Harries M.
        • Taylor A.
        • Holmberg L.
        • et al.
        Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients.
        Cancer Epidemiol. 2014; 38: 427-434
        • Li B.T.
        • Wong M.H.
        • Pavlakis N.
        Treatment and prevention of bone metastases from breast cancer: a comprehensive review of evidence for clinical practice.
        J Clin Med. 2014; 3: 1-24
        • Cardoso F.
        • Costa A.
        • Norton L.
        • et al.
        ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
        Ann Oncol. 2014; 25: 1871-1888
        • Aapro M.
        • Finek J.
        Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results.
        Cancer Treat Rev. 2012; 38: 120-126
        • Pajk B.
        • Cufer T.
        • Canney P.
        • et al.
        Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
        Breast. 2008; 17: 180-185
        • Hammond M.E.
        • Hayes D.F.
        • Dowsett M.
        • et al.
        American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
        Arch Pathol Lab Med. 2010; 134: e48-e72
        • Clemons M.J.
        • Cochrane B.
        • Pond G.R.
        • et al.
        Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
        Breast Cancer Res Treat. 2014; 146: 153-162
        • Baselga J.
        • Campone M.
        • Piccart M.
        • et al.
        Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
        N Engl J Med. 2012; 366: 520-529
        • Piccart M.
        • Hortobagyi G.N.
        • Campone M.
        • et al.
        Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.
        Ann Oncol. 2014; 25: 2357-2362
        • Gnant M.
        • Baselga J.
        • Rugo H.S.
        • et al.
        Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
        J Natl Cancer Inst. 2013; 105: 654-663
        • Campone M.
        • Bachelot T.
        • Gnant M.
        • et al.
        Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
        Eur J Cancer. 2013; 49: 2621-2632
        • Turner N.
        • Turner N.C.
        • Ro J.
        • et al.
        • PALOMA3 Study Group
        Palbociclib in hormone-receptor-positive advanced breast cancer.
        N Engl J Med. 2015; 373: 209-219
        • Cristofanilli M.
        • Turner N.C.
        • Bondarenko I.
        • et al.
        Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
        Lancet Oncol. 2016; 17: 425-439
        • Finn R.
        • Martin M.
        • Rugo H.R.
        • et al.
        PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC).
        J Clin Oncol. 2016; 34 (Abstract 507)